Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Flumatinib vs Imatinib in Ph+ ALL
NCT05071482Phase 4Terminated
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- Sep 2021
- Primary completion
- Jan 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of Flumatinib in Acute lymphoblastic leukemia, Philadelphia chromosome positive, sponsored by Institute of Hematology and Blood Diseases Hospital. Started Sep 2021; status: terminated.
02
Drugs
Flumatinib
03
Conditions
Acute lymphoblastic leukemia, Philadelphia chromosome positive
Beyond the preview
Go deeper on NCT05071482.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05071482.